Global Women's Health Academy

A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results

A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results
RestartResume

A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.

  • Overview

    A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.

    Schiffman M, Vaughan LM, Raine-Bennett TR, Castle PE, Katki HA, Gage JC, Fetterman B, Befano B, Wentzensen N.

    Gynecol Oncol. 2015 Sep;138(3):573-8. doi: 10.1016/j.ygyno.2015.06.040. Epub 2015 Jul 4.

    Abstract

    BACKGROUND:

    In US cervical screening, immediate colposcopy is recommended for women with HPV-positive ASC-US(equivocal) cytology. We evaluated whether partial typing by Onclarity™ (BD) might identify HPV-positive women with low enough CIN3+ risk to permit 1-year follow-up instead.

    METHODS:

    The NCI-Kaiser Permanente Northern California Persistence and Progression cohort includes a subset of 13,890 women aged 21+ with HC2 (Qiagen)-positive ASC-US at enrollment; current median follow-up is 3.0years. Using stratified random sampling, we typed 2079 archived enrollment specimens including 329 women subsequently diagnosed with CIN3+, 563 with CIN2, and 1187 with <CIN2. Adjusting for sampling, we computed 3-year cumulative CIN3+ risks for each Onclarity typing channel, using Kaplan-Meier methods.

    RESULTS:

    The 3-year CIN3+ risk for all HC2-positive women with ASC-US was 5.2%; this establishes the "benchmark" risk for colposcopic referral. Hierarchically, 3-year cumulative risks for each typing channel were 16.0% for HPV16, 7.4% for HPV18, 7.0% for HPV31, 7.1% for grouped HPV33/58, 4.3% for HPV52, 3.9% for HPV45, 2.7% for HPV51, 1.6% for HPV39/68/35, and 1.3% for HPV59/56/66.

    DISCUSSION:

    ASC-US linked to HPV16, HPV18, HPV31, or HPV33/58 warrants immediate colposcopy. Optimal management of women with HPV52 or HPV45 is uncertain. Risk of women with only HPV51, HPV39/68/35, or HPV59/56/66 might be low enough to recommend 1-year retesting permitting viral clearance. This strategy would defer colposcopy for 40% of women with HPV-positiveASC-US, half of whom would be cotest-negative at 1-year return. Approximately 10% of those with CIN3 diagnosable at enrollment would be delayed 1year instead. Cost-effectiveness analyses are needed.

    Published by Elsevier Inc.

  • Commercial Support

    This activity is supported by an independent educational grant from BD Life Sciences.

Facebook Comments

Register

We’re glad to see you’re enjoying Global Women's Health Academy…
but how about a more personalized experience?

Register for free